Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07429708 Ropivacaine Hydrochloride Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07429708 clinical trial report covering Ropivacaine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07428499 Onvuzosiran Hereditary Angioedema Types I and II Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07428499 clinical trial report covering Onvuzosiran, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07429734 Solifenacin Succinate Urinary Bladder, Overactive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07429734 clinical trial report covering Solifenacin Succinate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2071250134 Selexipag Intermittent Claudication Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
JPRN-jRCT2071250134 clinical trial report covering Selexipag, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07431281 Nivolumab Claudin18.2-positive / HER2-negative Solid Tumors Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07431281 clinical trial report covering Nivolumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2071250135 Selexipag Intermittent Claudication Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
JPRN-jRCT2071250135 clinical trial report covering Selexipag, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07430956 Cenvacibart Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07430956 clinical trial report covering Cenvacibart, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07430306 Anifrolumab-FNIA Systemic Lupus Erythematosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07430306 clinical trial report covering Anifrolumab-FNIA, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07428746 Semaglutide (Novo Nordisk) Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07428746 clinical trial report covering Semaglutide (Novo Nordisk), Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07434050 Ecnoglutide Sleep Apnea, Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07434050 clinical trial report covering Ecnoglutide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07432087 Cetuximab Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07432087 clinical trial report covering Cetuximab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07433413 Naltrexone Hydrochloride Alcohol Use Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07433413 clinical trial report covering Naltrexone Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.